Search results
Results from the WOW.Com Content Network
Vaccination of dogs is the practice of animal vaccination applied to dogs. Programs in this field have contributed both to the health of dogs and to the public health . In countries where routine rabies vaccination of dogs is practiced, for example, rabies in humans is reduced to a very rare event.
The most effective malaria vaccine is the R21/Matrix-M, with a 77% efficacy rate shown in initial trials and significantly higher antibody levels than with the RTS,S vaccine. It is the first vaccine that meets the World Health Organization's (WHO) goal of a malaria vaccine with at least 75% efficacy, [6] [7] and only the second malaria vaccine ...
Dengue vaccine is a vaccine used to prevent dengue fever in humans. [9] Development of dengue vaccines began in the 1920s but was hindered by the need to create immunity against all four dengue serotypes. [10] As of 2023, there are two commercially available vaccines, sold under the brand names Dengvaxia and Qdenga. [11] [12]
This vaccine is the first to meet the World Health Organization's Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy. [145] Germany-based BioNTECH SE is developing an mRNA-based malaria vaccine BN165 [146] which has recently initiated a Phase 1 study [clinicaltrials.gov identifier: NCT05581641] in December 2022. The ...
[3] [4] Vaccines are categorised into conventional and next generation vaccines. [5] [6] Animal vaccines have been found to be the most cost effective and sustainable methods of controlling infectious veterinary diseases. [6] In 2017, the veterinary vaccine industry was valued at US$7 billion and it is predicted to reach US$9 billion in 2024. [7]
This page was last edited on 23 September 2021, at 18:23 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
One challenge in vaccine development is economic: Many of the diseases most demanding a vaccine, including HIV, malaria and tuberculosis, exist principally in poor countries. Pharmaceutical firms and biotechnology companies have little incentive to develop vaccines for these diseases because there is little revenue potential.
Language links are at the top of the page across from the title.